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Abstract
Background: Transgenic mice expressing mutated amyloid precursor protein (APP) and presenilin (PS)-1 or -2 have been
successfully used to model cerebral b-amyloidosis, one of the characteristic hallmarks of Alzheimer’s disease (AD) pathology.
However, the use of many transgenic lines is limited by premature death, low breeding efficiencies and late onset and high
inter-animal variability of the pathology, creating a need for improved animal models. Here we describe the detailed
characterization of a new homozygous double-transgenic mouse line that addresses most of these issues.
Methodology/Principal Findings: The transgenic mouse line (ARTE10) was generated by co-integration of two transgenes
carrying the K670N/M671L mutated amyloid precursor protein (APPswe) and the M146V mutated presenilin 1 (PS1) both
under control of a neuron-specific promoter. Mice, hemi- as well as homozygous for both transgenes, are viable and fertile
with good breeding capabilities and a low rate of premature death. They develop robust AD-like cerebral b-amyloid plaque
pathology with glial inflammation, signs of neuritic dystrophy and cerebral amyloid angiopathy. Using our novel image
analysis algorithm for semi-automatic quantification of plaque burden, we demonstrate an early onset and progressive
plaque deposition starting at 3 months of age in homozygous mice with low inter-animal variability and 100%-penetrance
of the phenotype. The plaques are readily detected in vivo by PiB, the standard human PET tracer for AD. In addition,
ARTE10 mice display early loss of synaptic markers and age-related cognitive deficits. By applying a c-secretase inhibitor we
show a dose dependent reduction of soluble amyloid b levels in the brain.
Conclusions: ARTE10 mice develop a cerebral b-amyloidosis closely resembling the b-amyloid-related aspects of human AD
neuropathology. Unifying several advantages of previous transgenic models, this line particularly qualifies for the use in
target validation and for evaluating potential diagnostic or therapeutic agents targeting the amyloid pathology of AD.
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Introduction
Alzheimer’s disease (AD), the most common form of dementia in
the elderly, is characterized by extracellular deposition of amyloid
plaques, the intracellular aggregation of neurofibrillary tangles
(NFTs) and loss of synaptic connections in the brain. Amyloid
plaquesareformed from amyloid b peptides(Ab), whicharecleaved
by b- and c-secretases from the amyloid precursor protein (APP).
Mutations in the genes of APP and presenilin 1 and 2 (PS1, PS2),
components of the c-secretase complex, are linked to familial early
onset AD (FAD) forms and have been shown to alter APP
processing by enhancing the formationof Abx-42 peptide (Ab42) [1].
Expression of human APP with single or double mutations in
transgenic mouse lines leads to the formation of diffuse and
neuritic plaques, which resemble the amyloid pathology seen in
brain material from AD patients [2]. The onset and severity of this
phenotype is further accelerated by crossing to mutant PS1 or PS2
transgenic mice [3]. These transgenic AD models have been
proven to be a valuable tool for evaluating the effects of potential
therapeutic agents, particularly targeting the amyloid pathology.
For instance, active and passive immunization approaches against
Ab have been developed and successfully validated in animal
models [1]. However, the use of many transgenic lines is limited by
low breeding efficiencies, high premature death, late onset and
high inter-animal variability of the pathology creating a need for
improved animal models addressing these questions [3,4].
An important consideration in the characterization of AD
transgenic mouse models is the qualitative and quantitative
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the brain is mainly quantified from total brain extracts by ELISA
or Western Blot analyses whereas plaque morphology is currently
best investigated in situ by immunohistochemistry or fluorescence
staining [5,6]. However, the plaque load, the number and size
distribution of plaques are very important parameters which are
not assessed by total Ab levels but may be altered upon therapeutic
intervention. Because conventional manual methods of plaque
counting are very time-consuming and prone to errors, rapid and
robust methods of quantitative plaque evaluation are required.
By neuron-specific over-expression of APPwith the swedish double
mutation (APPswe, K670N + M671L) and PS1 carrying the M146V
mutation we have generated a double transgenic mouse line,
ARTE10, which can be maintained homozygous for both transgenes.
In order to characterize the amyloid pathology of the model, we
established a semi-automated image analysis procedure that
specifically and reproducibly quantifies plaque loads, plaque sizes
and numbers in stained histological sections. Applying this novel
method, we here demonstrate that ARTE10 mice consistently
develop an early-onset and rapidly progressive AD-like cerebral b-
amyloidosis with low inter-animal variability. Based on the
p h e n o t y p i cc h a r a c t e r i s t i c so ft h em o u s el i n ew es u g g e s tt h a tA R T E 1 0
is a mouse model well suited for studying amyloid-lowering therapies
and presumably also for validation of new target candidates.
Materials and Methods
Animals
All experiments were done in accordance with the European
Communities Council Directive of 24 November 1986 (86/609/
EEC) and with the approval of the local institutional animal care
committees (Landesamt fu ¨r Natur, Umwelt und Verbrau-
cherschutz, North Rhine-Westphalia, Regierung von Oberbayern,
Munich, Amt fu ¨r Gesundheit und Verbraucherschutz, Hamburg,
Germany; Kantonales Veterina ¨ramt Zurich, Switzerland). All
efforts were made to minimize the number of animals used and
their suffering.
Generation of Transgenic Mice
To generate both transgenic constructs, the human APPswe and
the human PS1M146V cDNAs respectively were cloned into the
XhoI site of an expression cassette containing the murine Thy-1.2
gene [7]. The insert of both constructs were removed from the
Vector backbone sequences by Not I digestion and gel purified
prior to pronucleus injection. B6;CB-Tg(Thy1-PSEN1*M146V/
Thy1-APP*swe)10Arte (ARTE10) mice were produced by pronu-
clear co-injection of Thy1-APPswe and Thy1-PS1M146V con-
structs into B6CBF1 eggs according to standard procedures [8].
Quantitative Genotyping
The relative quantity of the human APPswe and the human
PS1M146V transgenes was determined using the LightCycler
technology (Roche Applied Science). First, standard curves were
generated to determine the efficiency of PCRs with specific primers
for APP: 59-AAGATGCAGCAGAACGGCT-39 and, 39-CA-
GATCTAGCTCCAGGAAGGAGA-59,a n df o rP S 1 :5 9-GAGC-
CCTCGAAATTCGTTGA-39 and 39-TATCTCTTGCCGTCC-
TCGTGT-5. PCR amplification (95uCa n d1s e c ,5 6 uCa n d5s e c ,
and 72uC and 5 sec) was performed in a volume of 20 ml containing
LightCycler-FastStart DNA Master SYBR Green I mix (Roche
Applied Science), 0.5 mM primers, 2 ml of a genomic DNA (gDNA)
dilution series of a hemizygous ARTE10 mouse and additional
3m MM g C l 2. Melting curve analyses of the PCR products revealed
single peaks at 82uC for APP,and 86uC for PS1 respectively, with no
visible primer dimers. Quality and size of the qPCR product were
determined applying the DNA 500 LabChip system using the 2100
Bioanalyzer (Agilent Technologies). Single peaks at the expected size
of 85 bp for APP, and 146 bp for PS1 were observed in the
electropherograms of the samples respectively. In an analogous
manner, the qPCR protocol was applied to determine the PCR
efficiency of murine APP gene intron, using the specific primers 59-
CCACAGGAGTTGCGGGAAT-39 and 59-AGTGTCTATC-
TACGGACCGAGT-39. Melting curve analysis revealed a single
peak at approximately 85uC with no visible primer dimers.
Bioanalyzer analysis of the PCR product showed one single peak
of the expected size (120 bp). For calculation of the standard values,
first the logarithm of the used gDNA concentration was plotted
againstthe threshold cycle value CtforAPP,PS1,anda murine APP
gene intron, respectively. The slopes and the intercepts of the
standard curves (i.e. linear regressions) were calculated.
In a second step, DNA amounts from controls and ARTE10
mouse gDNA samples were analyzed in parallel. The Ct values
were measured and converted to ng gDNA using the correspond-
ing standard curves: 10
‘ (Ct value - intercept)/slope [ng gDNA].
Calculated gDNA concentration values of APP, and PS1, each
were normalized to murine APP gene intron that was analyzed in
parallel for each tested DNA probe, thus resulting values are
defined as relative DNA levels.
Antibodies
The following antibodies were used for immunofluorescence or
-histochemistry: mouse anti-Ab clone 4G8 (Signet), mouse anti-Ab
clone 6E10 (Signet), rabbit anti-Ab (x-40) C-terminus-specific
polyclonal 44–348 (Biosource), rabbit anti-Ab (x-40) AB2050P
(Araclon Biotech), rabbit anti-Ab (x-42) C-terminus-specific
polyclonal 44–344 (Biosource), mouse anti-Ab (x-42) G2-13 (The
Genetics Company), rabbit anti-Ab polyclonal AB1 (Araclon
Biotech), rabbit anti-oligomer conformation-specific polyclonal
A11 (Invitrogen), mouse anti-APP near N-terminus (human-
specific) clone LN27 (Zymed/Invitrogen), rabbit anti-APP near
C-terminus (human, mouse) polyclonal AB5352 (Chemicon),
mouse anti-tau (pS202) clone AT8 (Pierce Endogen), mouse
anti-ubiquitin clone Ubi-1 (Zymed/Invitrogen), goat anti-AIF1
(anti-Iba1) polyclonal ab5076 (Abcam), rabbit anti-GFAP poly-
clonal AB5804 (Chemicon). Fluorophore-coupled donkey-anti-
mouse, anti-rabbit or anti-goat antibodies were used as secondary
antibodies. Antibodies were coupled to either Alexa488 (Molecular
Probes), Cy3 or Cy5 (both Jackson ImmunoResearch).
Immuno- and Amyloid-Staining
5 mm-thick paraffin sections from mouse brain hemispheres
were used for all immuno- and amyloid stainings. Sections were
stained with 1% Thioflavin S solution for 30 min at RT. Congo
red amyloid staining was performed according to the method
described by Puchtler et al. [9] by immersion in an alkalinized
NaCl-saturated 80%-ethanolic solution of 0.2% Congo red for
15 min. Epitope retrieval by pretreatment with 70% formic acid
(100264, Merck) for 15 min at RT was required in order to
enhance the immunoreactivity of any anti-Ab antibody used here;
this formic acid pretreatment had no major influence (besides
some slight signal enhancement) on the specific immunoreactivities
of the antibodies used for the detection of ubiquitin (Ubi-1),
abnormally phosphorylated tau (AT8), activated microglia (AIF1/
Iba1) or reactive astrocytes (GFAP). Alternatively, heat-induced
epitope retrieval in a pressure cooker with pH 6.0 sodium citrate
buffer for 15 min was used in order to enhance the specific
immunoreactivities of antibodies LN27 and AB5352. Immuno-
peroxidase staining was done using the HistoMouse-MAX kit
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with the following modification: HistoGreen (Linaris) was used as
chromogenic substrate and nuclear fast red (NFR, N-8002, 0.1%
in aqueous solution containing 5% aluminium sulphate, Fluka/
Sigma) was employed as counterstain. Stained sections were
dehydrated through ascending ethanol (70%, 96%, absolute),
cleared in two changes of xylene and mounted with Histomount
(Zymed/Invitrogen).
For immunofluorescence stainings, sections were blocked with
3% bovine serum albumin (BSA, Fluka/Sigma) in PBS for 15 min
and probed with one, two or three simultaneous primary
antibodies diluted in 1% BSA/PBS over night at 4uC, washed
with PBS, blocked again with 3% BSA/PBS and incubated with
one, two or three simultaneous fluorophore-conjugated secondary
antibodies, washed, and coverslip-mounted with ProLong Gold
Antifade mounting medium (Invitrogen/Molecular Probes). Op-
tionally, nuclei were stained by adding 0.5 mM DAPI (32670,
Fluka/Sigma) before the last washing steps. HistoGreen/NFR-
stained sections were scanned with the Minolta Dimage Scan Elite
5400 slide scanner at highest resolution (5400 dpi, corresponding
to approximately 5 mm per pixel) in the colour positive mode, for
which purpose the slide scanning rack had been adapted to hold 3
standard microscope slides. Fluorescence or brightfield microscopy
was performed with an Olympus BX51 or Zeiss AxioImager Z.1
microscope. Digital micrographs were acquired with a ColorView
II charge-coupled display (CCD) camera (Soft Imaging System,
Olympus) or AxioCam MRm Rev. 3.0 (Carl Zeiss). Entire-view
micrographs of parasagittal forebrain sections were recorded
through a 2x objective followed by a 0.5x TV adaptor.
Image Analysis and Plaque Quantification
Digital images were evaluated with the Acapella
TM data analysis
software (Evotec Technologies, Fig. S2). An object-based algorithm
was developed for the specific and sensitive recognition of individual
plaques and for the quantitative assessment of the relative plaque load,
calculated as the percentage of the area covered by plaques over the
total area of interest (i.e. the sum of pixels representing plaque signals
divided by the sum of all pixels representing the region of interest), the
number of individual plaques per area and their size distribution.
Regions of interest (namely, the neocortex and the hippocampus) were
defined by manual segmentation in accordance with the anatomical
delineations given by Paxinos and Franklin (1997) [10] using a state-
of-the-art image editing software (Adobe PhotoShop CS). The
resulting region-of-interest images were converted from RGB into
HSV format and split into the three corresponding 8-bit channels
respectively representing the hue, the saturation and the intensity
value of each pixel. The combination of different parameters from two
different channels ensured both high sensitivity and specificity of
plaque recognition. Detection of HistoGreen-stained plaques was
most sensitive and robust in the hue channel, and the specificity of
separation from the pink-red counterstained tissue background was
also optimalin the hue channel. The saturation channel,however,was
best suited for discriminating and eliminating contaminations or
otherwise interfering signals e.g. resulting from dust particles, small
irregularities or folds in the tissue section, hence further enhancing the
specificity of plaque recognition. A three-step algorithm was designed.
In a first step, individual global thresholds were dynamically generated
and applied to each channel in order to create masks which were
subsequently combined through an adequate set ofoperationsin order
to find a good overall approximation of plaque locations. As a side
effect of ensuring maximum sensitivity of detection, the resulting
preliminary plaques were generally somewhat overestimated in size,
and clusters of closely neighbored individual plaques were sometimes
coalesced to simulate one or more giant plaques. To correct for this
error, in a second step, the topology of individual and between-plaque
borders was determined by reducing the preliminary plaques to few
extremal points, typically approximating individual or local barycen-
ters, and by using these points as seeds for a conventional watershed
algorithm. Growth of watershed basins was restricted to the
preliminary plaque contours. In a third step, each object having
passed step two was checked for its plaque-likeness on a rough
morphometrical plane, and objects that were too small or extremely
skewed were presumed to be unspecific and therefore removed. All
other objects were recognized as plaques, and the plaque size (pixel
count) was recorded for quantitative analyses specified above. A lower
limit for meaningful plaque detection was determined by direct
microscopic evaluation of the sections with the lowest plaque loads.
The visually confirmed threshold was set at 0.005% (plaque area per
area of interest). At least six standardized parasagittal sections
containing major portions of the neocortex and hippocampus were
analyzed per animal and mean values were generated for each
individual.
Differential Extraction of Ab x-40 and Ab x-42 Peptides
Frozen brain hemispheres were homogenized in 19 volumes of
tris buffer (150 mM NaCl, 20 mM Tris pH 8.0+ Complete,
Roche Applied Science) using a Dounce glass homogenizer with a
Teflon pestle and centrifuged at 53000 rpm (TLA-120.2 rotor,
Beckmann) for 30 min at 4uC. Pellets were resuspended in the
same volume of 70% formic acid, kept on ice for 30 min and
centrifuged likewise. Supernatants were neutralized with 19
volumes of 1 M Tris pH 11.3. Ab peptides were quantified in
supernatants of both extractions using commercially available
ELISA kits (hAmyloid b40 ELISA TK40HS, hAmyloid b42
ELISA TK42HS, The Genetics Company) recognizing human
but not endogenous murine Ab. Total protein was measured using
a protein detection kit (BCA test, Pierce) and results are expressed
as pg Ab per mg protein.
Substance Application
The c-secretase inhibitor MRK-560/compound 32 [11] was
used. 3 to 7 months old hemizygous ARTE10 mice received either
vehicle (10% ethanol in corn oil), 1, 10, 30 or 100 mg/kg MRK-
560 suspended in vehicle solution by oral gavage at 10 ml/kg.
After 4 h brains were excised and the amount of soluble Ab was
determined as described above using the brain lysis buffer from the
ELISA kit (The Genetics Company).
Ex Vivo Autoradiography
A 17 months old hemizygous female ARTE10 mouse (29.7 g)
received about 100 ml of a solution containing 0.4660.02 MBq of
N-[
3H-methyl]-6-OH-BTA-1[12] in PBS through one of its lateral
tail veins. The animal was guillotined at 40 min post-injection, the
full brain was removed, rapidly frozen in dry ice and stored for
three days in air-tight vials at 275uC until sectioning. For tissue
analyses, the brain was cut into 10 mm coronal sections on a
cryostat (Leica Microsystems). The frozen sections were thaw-
mounted on dilute poly-L-lysine coated (mol wt .300.000, (1:50)
0.01%w/v in water, Fluka/Sigma) microscopy slides, dried in
ambient air and stored at 275uC. The deep frozen CNS sections
were dried at ambient conditions for 30 min and subsequently
covered with scintillation foil. Digital autoradiography images
were acquired with the M40 series of m-Imager
TM (Biospace lab,
France). The resolution with tritium is 20 mm, the detection
threshold for tritium is 0.4 cpm/mm
2 and the smallest pixel size is
1 mm. Data acquisition was controlled with m-Acquisition
software. The data was exported with b-Vision+ software (both
from Biospace Lab, France) for processing in Adobe Photoshop
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qPCR Expression Analysis
Brain tissue dissection. Brain tissues from ARTE10 mice
and control subjects, were collected. Sample sections from each
tissue were fixed in paraformaldehyde. Brain areas for mRNA
expression analysis were stored at -80uC until RNA extractions
were performed.
Isolation of total mRNA. Total RNA was extracted from
frozen brain tissue by using the RNeasy kit (Qiagen) according to
the manufacturer’s protocol. The accurate RNA concentration
and the RNA quality were determined applying the Eukaryote
total RNA Nano LabChip system by using the 2100 Bioanalyzer
(Agilent Technologies). For additional quality testing of the
prepared RNA, i.e. exclusion of partial degradation and testing
for DNA contamination, specifically designed intronic GAPDH
oligonucleotides and genomic DNA as reference control were
utilized to generate a melting curve with the LightCycler
technology (Roche Applied Science) as described in the supplied
protocol by the manufacturer.
cDNA synthesis. Here, total RNA was used as starting
material, which had been extracted as described above. For
production of cDNAs, the cDNA Synthesis System was performed
according to the manufacturer’s protocol (Roche Applied Science).
The accurate cDNA concentration was determined by photometric
analysis (OD 260/280 nm).
Quantitative RT-PCR. mRNA expression analyses of the
genes coding for Synaptophysin (Syp), Disk large homolog 4
(Dlgh4), and Drebrin (Dbn1) were performed using the
LightCycler technology (Roche Applied Science). The relative
quantity was determined as following. First, standard curves were
generated to determine the efficiency of PCRs with specific
primers for Syp: 59-TCCCTCTGCCCCTCCTAACT-39 and, 39-
GTTCTCATCTCCCCACCTCCAC-59, for Dlgh4: 59-GCA-
CCGACAACCCACACAT-39 and 39-CAGTTACTTCACCT-
ACAGGCC-59, and for Dbn1: 59-GGAGATGAAGCGG-
ATTAACCG-39 and 39-TTCTTCCGAGACCTGCGGT-59.
PCR amplification (95uC and 1 sec, 56uC and 5 sec, and 72uC
and 5 sec) was performed in a volume of 20 ml containing
LightCycler-FastStart DNA Master SYBR Green I mix (contains
FastStart Taq DNA polymerase, reaction buffer, dNTP mix with
dUTP instead of dTTP, SYBR Green I dye, and 1 mM MgCl2;
Roche Applied Science), 0.5 mM primers, 2 ml of a cDNA dilution
series from mouse total brain and additional 3 mM MgCl2 (for
Dbn1 1 mM MgCl2). Melting curve analyses of the PCR products
revealed single peaks at 84uC for Syp, 87.5uC for Dlgh4, and
86.5uC for Dbn1 respectively, with no visible primer dimers.
Quality and size of the qPCR product were determined applying
the DNA 500 LabChip system using the 2100 Bioanalyzer (Agilent
Technologies). Single peaks at the expected size of 103 bp for Syp,
134 bp for Dlgh4, and 98 bp for Dbn1 were observed in the
electropherograms of the samples respectively. In an analogous
manner, the qPCR protocol was applied to determine the PCR
efficiency of Cyclophilin B (Ppib), using the specific primers 59-
GATGTCATCATTGTCGACTCCG-39 and 59-GCTCTCTAC
TCCTTGGCAATGG-39. Melting curve analysis revealed a
single peak at approximately 83.5uC with no visible primer
dimers. Bioanalyzer analysis of the PCR product showed one
single peak of the expected size (71 bp). For calculation of the
standard values, first the logarithm of the used cDNA concentra-
tion was plotted against the threshold cycle value Ct for Syp,
Dlgh4, Dbn1, and Ppib, respectively. The slopes and the intercepts
of the standard curves (i.e. linear regressions) were calculated.
In a second step, mRNA expression from controls and ARTE10
mouse brain samples were analyzed in parallel. The Ct values were
measured and converted to ng total brain cDNA using the
corresponding standard curves: 10
‘ (Ct value - intercept)/slope
[ng total brain cDNA]. Calculated cDNA concentration values of
Syp, Dlgh4, and Dbn1, each were normalized to Ppib that was
analyzed in parallel for each tested tissue probe, thus resulting values
are defined as arbitrary relative expression levels.
Behavioral Analyses
Three cohorts of hemizygous and homozygous transgenic mice
as well as wild type litter mates were analyzed. One cohort was
repeatedly tested in a longitudinal study design at 4, 8 and 12
months of age. The other cohorts were analyzed in a cross-
sectional study at 8 and 12 months respectively. Number for each
group were: longitudinal cohort, 15 wild type (5 females+10
males), 16 hemizygous (8 females + 8 males), 13 homozygous (9
females + 4 males, 2 females died before the age of 12 months);
cross-sectional cohort at 8 months, 14 wild type (5 females+9
males), 15 hemizygous (5 females + 10 males), 12 homozygous (5
females + 7 males); cross-sectional cohort at 12 months, 14 wild
type (9 females + 5 males), 14 hemizygous (9 females + 5 males), 14
homozygous (8 females + 6 males). All mice were age-matched and
were tested in an identical test battery.
TheMorriswatermazetestwasperformedinacircularswimtank
(diameter 150 cm, height 50 cm), the quadratic target platform
(14614 cm) was made of metallic wire mesh and was hidden 0.5 cm
below the water surface in the center of one of four pool quadrants
(target quadrant). A circular zone of 53 cm in diameter around the
target platform was defined as target zone (12.5% of the total area of
the pool). Movement of the mice was tracked by a video camera and
EthoVision Software (Noldus, Netherlands), data analysis was
done with Wintrack Software [13]. Each mouse was trained for a
total of 18 training trials to find the position of the hidden platform
which remained fixed for each animal throughout all trials of the
task. Aprobetrialwas conducted onday4 inwhichthe platformwas
removed from the pool and the path that each mouse swam was
recorded over a 60 sec period. In the longitudinal study the position
of the escape platform for each animal was changed at each of the
three time points.
The object recognition test was performed in the open field box
(50650650 cm). After a habituation session animals were placed
for 10 min into the box with two identical objects. A recall session
was conducted 24 h later in which one object was replaced by a
new object. Activity was recorded and analyzed using a video
camera and EthoVision Software (Noldus, Netherlands) while
exploration was scored manually. Exploration was defined as
approach to an object with the animal’s head at a minimum
distance of 1 cm. Preference for the new versus the old object was
calculated according to the following formula: preference =
exploration time new object/total exploration time.
Statistical Analyses
Unless otherwise noted, statistical analyses of means + SEM
were done using StatView statistical software (SAS Institute). In
case of normally distributed data One-Way ANOVA for genotype
or dosage was performed for single measures at each time point,
repeated measures ANOVA for several data points for each
animal within one test. Fisher’s PLSD was used for post-hoc
analysis. Use of unpaired t-test was indicated where appropriate.
One-sample t-tests were performed to test significance in
comparison to chance level. Regression diagnostic was done using
S-Plus 8.0.4 for Linux. Non-parametric Mann-Whitney test (two-
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Prism 4 (GraphPad Software, Inc).
Results
Generation of Transgenic Mice
Several independent transgenic founder lines were established
by co-injection of human APPswe and PS1M146V each driven by
the Thy-1 promoter. In all tested lines, the two transgenes were co-
inherited without segregation over several generations. Expression
of the transgenes was analyzed by Northern blot analysis and
independent transgenic lines were initially screened for formation
of amyloid plaques in the brain by congo red staining (data not
shown). Based on high expression level and early plaque formation
line ARTE10-729 was selected for propagation and subsequent
analysis. Breeding performance of this line was indistinguishable
from C57BL/6 mice, even when retained as a homozygous line
(C57Bl/6: 3.060.2 pups per female per month, hemizygous
ARTE10: 3.560.4 pups per female per month, homozygous
ARTE10: 3.160.4 pups per female per month). Also, the rate of
premature death was quite low in this line. During the longitudinal
study all hemizygous ARTE10 mice reached the age of 12 months
(100% survival) and survival was also 100% in the wild type
littermate group, whereas only 2 out of 13 homozygous ARTE10
mice died before the age of 12 months (85% survival).
Assessment of Transgene Expression in ARTE10 Brain
Transgene expression was analyzed by double-immunofluores-
cent labeling of human APP and MAP2, a specific somato-
dendritic marker of all CNS neurons, on brain sections of
ARTE10 mice. The transgenic human protein was abundantly
and selectively expressed by the vast majority (.80%) of neurons
in the hippocampus (Fig. 1a) and by approximately 50% of
neurons in the neocortex (data not shown). No transgenic protein
was detectable in non-neuronal cells in the brain, particularly glial
and vascular smooth muscle or endothelial cells, confirming
neuron-specific transgene expression (Fig. S1).
AD-Like Ab-Related Neuropathology, Morphology of and
Composition of b-Amyloid Plaques
ARTE10 mice developed cerebral b-amyloidosis with similar
morphology and composition as in human AD-affected brain,
including mainly dense-core, and to a lesser extent diffuse plaques
as well as amyloid angiopathy. The plaques were composed of Ab
peptide (both Ab40 and Ab42 forms, Fig. 1e–h and Fig. S3), and
their amyloid nature was evidenced by staining with congo red,
imparting the characteristic green bi-refringence in polarized light
(Fig. 1b), or with thioflavin S (Fig. 1c–d, Fig. S4). Diameters of the
congophilic plaque cores ranged from 5 to 200 mm, averaging
between 20 and 50 mm.
The dense-core plaques were each encompassed by a sphere
(corona) of early-dystrophic, swollen neurites featuring pro-
nounced accumulation of ubiquitin (Fig. 1c–d, Fig. S4) and
synaptophysin (Fig. S5). In ageing homozygous ARTE10 mice, a
minority of dystrophic neurites contained AT8-positive material,
indicating nascent tau hyperphosphorylation (Fig.1e–f). However,
argyrophilic neurites, tangles or neuropil threads were not
observed even in animals aged up to 20 months.
Diffuse plaques, i.e. accumulations of Ab peptide lacking a
congophilic core, were only observed in the presence of very high
total plaque loads, forming small satellite deposits in proximity to
dense-core plaques. Like in human brain, diffuse deposits were
composed almost exclusively of Abx-42 species (Fig. S3). However,
diffuse deposits were absent from ARTE10 brains with low plaque
burden or with beginning plaque deposition, where even the
earliest and smallest detectable Ab deposits already consisted of
mature, congophilic amyloid (Fig. 1b+d, Fig. S4).
All amyloid plaques were accompanied by marked mixed glial
inflammation with many activated microglia and reactive
astrocytes populating the outer plaque spheres (Fig. 1g–h, Fig.
S4). Additional cerebral amyloid angiopathy of intracortical,
leptomeningeal and choroidal blood vessels regularly occurred in
ARTE10 mice with advanced plaque deposition (arrow in Fig. 1c).
Intracellular Ab was detected in several pyramidal neurons of the
cortex and hippocampus. This intraneuronal Ab immunoreactivity
was found already in young ARTE10 mice. It exhibited a speckled
pattern within the perikarya. Interestingly, some neurons showed a
similar pattern of intracytoplasmic immunoreactivity with the anti-
oligomer conformation-specific antibody A11 (Fig. S6).
Pattern and Sequence of Plaque Deposition
The spatio-temporal development of cerebral amyloid plaque
pathology was monitored by histological examination of hemizy-
gous and homozygous ARTE10 mouse brains at different ages
(Fig. 2a–c, Fig. S7+S8).
The first plaques always occurred in the anterior neocortex and
in the subiculum as early as 3 and 5 months after birth in
homozygous and hemizygous animals, respectively, shortly
followed by the posterior neocortex, the CA1-4 regions of the
hippocampus, the amygdala and related limbic structures, and the
thalamus. Brain regions that were affected later include the
olfactory bulb, the colliculi, the brainstem, and the striatum, where
mainly ventral parts of the putamen developed plaques. At
advanced stages, i.e. from 8 months onward in homozygous
followed by hemizygous mice 2–3 months later, the largest plaques
were regularly observed in the thalamus. These giant plaque cores
were sometimes subject to microcalcification, a phenomenon that
was never observed in any other brain region. The regions that
were affected first consistently maintained their lead over the
regions that became affected later, i.e. the anterior neocortex and
the subiculum always showed the highest plaque densities. Plaques
were never observed in the cerebellum.
Quantification of Plaque Load
In order to quantitatively evaluate plaques visualized immuno-
histochemically in brain sections, a computerized image analysis
and object recognition algorithm was designed (Fig. S2).
We analyzed the neocortex and the hippocampus from a total of
176 hemizygous or homozygous ARTE10 mice of different ages
ranging from 3 to 20 months. The plaque load progressively
increased with age, exhibiting saturation kinetics (Fig. 2d). The
onset, rate and maximum levels of plaque deposition were
transgene dose-related, i.e. starting earlier, increasing faster and
peaking higher in the homozygous as compared to the hemizygous
condition. The same correlation was revealed for the number and
average size of plaques (Fig. 2e, f). 100% penetrance of the plaque
phenotype could be observed by 5 and 10 months of age in
homozygous and hemizygous mice, respectively. Aged ARTE10
mice of 19–20 months reached plaque loads of 10.5% (+/2 2.2%,
range 0.2–35.6%) in hemizygous mice and 35.2% (+/2 2.8%,
range 26.4–53.2%) in homozygous animals.
Comparison of Plaque Load to Ab Levels in Brain
Homogenates
Brain homogenates of 12 months old ARTE10 mice were
subjected to biochemical quantification of human Ab40 and
Ab42. Differential extraction procedures were applied in order to
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species. More soluble and insoluble Ab was detected in the brains
of homozygous in comparison with hemizygous transgenic animals
(Fig. 3a, b). The ratio of insoluble Ab42 to Ab40 was
approximately 1.5 and comparable between homozygous and
hemizygous mice (Fig. 3b). Hemizygous mice of different ages,
ranging from 4 to 15 months, were used in order to mutually cross-
validate the histology image-based plaque load quantification with
biochemical analyses (Fig. 3c, d). Both hemispheres of each mouse
brain were employed, one for histological plaque quantification,
the other for biochemical measurement of insoluble Ab. The
results of the corresponding hemispheres per animal were
compared directly. Levels of insoluble Ab40 and Ab42 strongly
correlated with the histological plaque burden as determined by
the image analysis confirming that both methods exhibit
equivalent quantitative power (Fig. 3c, d).
Figure 1. Amyloid pathology and glial inflammation in ARTE10 mouse brain. A, Double-immunofluorescent colocalization of the
transgenic human APP (red, human-specific antibody against the N-terminal ectodomain) with the neuron-specific somato-dendritic marker MAP2
(green) in the subiculum and the CA1 region of the hippocampus. The transgene is amply expressed in most (.80%) neurons (yellow merge colour),
whereas non-neuronal cells show no signals beyond background. B, Congo-red stained plaque core (red) in the frontal cortex of a hemizygous
ARTE10 mouse at 5 months of age. The green bi-refringence in polarized light (inset) is diagnostic of amyloid. C, D, Thioflavin-S positive plaque cores
(green), each encircled by a sphere (corona) of dilated, strongly ubiquitin-positive dystrophic neurites (red) in the subiculum of a homozygous ARTE10
mouse at 3 months of age (D) and in the frontal cortex of a 19 months old hemizygous mouse (C), the latter with concomitant amyloid angiopathy
(arrow). E, F, AT8-positive hyperphosphorylated tau (red) in dystrophic neurites adjacent to plaque cores (green:A b40 and Ab42) in homozygous
ARTE10 mice at 12 (E) and 8 (F) months of age. G, H, Triple-immunofluorescent demonstration of plaque-associated mixed glial inflammation:
Activated microglia (green, AIF1/Iba1) and reactive astroglia (magenta, GFAP) colonizing the periphery of amyloid cores (red:A b/6E10) in the subicula
of a homozygous 5 months (G) and a hemizygous 13 months (H) old ARTE10 animal (blue: nuclei/DAPI). Scale bar, 20 mm.
doi:10.1371/journal.pone.0007931.g001
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3H]PIB Distribution in the Brain Parenchyma of ARTE10
Mice
In order to evaluate potential use of ARTE10 mice for in vivo
analyses of amyloid plaques, [
3H]PIB, a specific Ab tracer, was
administered intravenously followed by ex vivo digital autoradiogra-
phy of brain sections. Amyloid-b plaques were shown as a dotted
pattern of focal tracer retention in the whole of the cortex and most
thalamic regions (Fig. 4a). The autoradiography method used here is
sufficient to resolve finer structures beyond the level of plaque
demarcation (Fig. 4, inlets). This picture correlated very well with the
distribution pattern and appearance of Ab40 and Ab42 in the
immune fluorescence staining of a parallel section close by (Fig. 4b).
Also, amyloid in vessels can clearly be seen in both modalities (Fig. 4a
and 4b, arrowheads). Hence, these data are consistent with the
anticipation that [
3H]PIBcrossed the blood-brainbarrier ofARTE10
mice and significantly bound to Ab plaques in these animals in vivo.
Expression Analysis of Pre- and Post-Synaptic Markers
Applyingreal-time quantitative PCR, the mRNA expression of
the presynaptic marker protein Synaptophysin (Syp) as well as
the postsynaptic markers Disk large homolog 4 (Dlgh4) and
Drebrin (Dbn1) were analyzed in brain samples from ARTE10
mice (Fig. 5, Fig. S9). Gene expression revealed that ARTE10
mice expressed Syp mRNA at a level of approximately 70% that
of wild type mice (i.e., a 30% reduction) and without any obvious
difference between hemi- and homozygous mice (Fig. 5a, Fig.
S9). The levels of Syp mRNA were shown to stay constant at all
ages examined. Gene expression analyses of Dlgh4 (Fig. 5b) and
Dbn1 (Fig. 5c) revealed a similar result of a decrease of
approximately 30% compared to Syp at early age points (Fig.
S9). In wild type mice mRNA expression levels of Dlgh4 and
Dbn1 were decreased with age whereas expression of Syp mRNA
stayed constant. In contrast, in transgenic mice mRNA
expression of all three synaptic markers revealed no further
decrease along with aging.
Behavioral Analyses
In both a longitudinal and a cross-sectional design, three cohorts
of mice were characterized in a battery of behavioral tests at
different ages (Fig. 6; results of sensorimotor, locomotory and
Figure 2. Onset and development of plaques in ARTE10 mice. A–C, Digital micrographs of parasagittal forebrain sections from homozygous
transgenic mice immunohistochemically stained for b-amyloid plaques (dark blue-green) at 3 (A), 8 (B), and 13 months of age (C). D–F Plaques are
quantified using Acapella
TM plaque recognition software in regions of interest on stained mouse brain sections. D, Plaque load is expressed as
percentage of plaque area per total area of neocortex and hippocampus across ages in homozygous (red) versus hemizygous mice (blue). Each symbol
represents one animal. Theaverage size(E) andnumberof plaques perarea (F) progressively increase with age in hemizygous (tg) andhomozygous (tg/
tg) ARTE10 mice. Data are expressed as means + SEM; * p,0.05, ** p,0.01, *** p,0.0005, tg versus tg/tg at the respective age (unpaired t-test).
doi:10.1371/journal.pone.0007931.g002
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and Tables S1 and S2).
A place navigation protocol measuring the spatial learning and
memory abilities of ARTE10 mice was performed in the Morris
water maze. Since swim speeds differed between groups at various
time points (data not shown), the animal’s path-length to reach the
platform were analyzed. At 4 and 8 months of age, mice of all
groups learned consistently to locate the platform during training
(Fig. 6a). By 12 months, a significant effect of genotype could be
found in the longitudinal study design (repeated measures
ANOVA, F(2,39)=3.48, p=0.041; post-hoc analysis wt vs. tg,
p=0.037, wt vs. tg/tg, p=0.024). Longer swim distances were
mainly needed at day 2 (unpaired t-test, wt vs. tg, p=0.57, wt vs.
tg/tg, p=0.015) but were comparable to controls at day 3. In
contrast, naı ¨ve ARTE10 mice were indistinguishable from controls
at 12 months of age. In the probe trial memory for the platform
location was determined. At 4 and 8 months of age all animals
displayed good memory as they swam significantly over chance
level (12.5%) in their respective target zones (Fig. 6b, p,0.05 for
all measures). By 12 months, mice of the longitudinal cohort were
indistinguishable from controls in memory retrieval. In contrast,
mice from the cross-sectional cohort displayed poor memory as
their preference for the target zone was borderline non-significant
over chance level (one sample t-test, hypothesized mean #12.5%;
wt, p=0.01; tg, p=0.052; tg/tg, p=0.052).
Episodic memory of mice from the cross-sectional cohorts was
examined in the object recognition test. Eight months old mice
displayed good memory of a previously explored object, indicated
by higher preference for a new versus the old object (Fig. 6c). By
the age of 12 months a deficit in episodic memory was evident in
homozygous ARTE10 mice as exploration of the new object was
not significant from chance level (one sample t-test, hypothesized
mean #50%; wt, p=0.0004; tg, p=0.002; tg/tg, p=0.293).
Treatment with a c-Secretase Inhibitor
The c-secretase inhibitor MRK-560/compound 32 [11] was
used in order to evaluate the ARTE10 model for its use in
assessing b-amyloid lowering therapies. After acute dosing with the
inhibitor levels of both soluble Ab40 and Ab42 were significantly
reduced in the brains of ARTE10 mice (Fig. 7). Ab40 levels were
reduced dosage-dependent up to 72% with an ED50 of 2.7 mg/
kg, whereas Ab42 secretion could only be inhibited by about 27%.
Figure 3. Correlation between insoluble Ab and plaque burden. A, B, Quantification of Ab peptides in brain extracts from hemizygous and
homozygous ARTE10 mice. 12 months old mice from the cross sectional study were used for the analysis. Soluble (A) and insoluble Ab (B) was
extracted with Tris buffer and formic acid, respectively, and the amount of Ab40 (open bars) and Ab42 (filled bars) was quantified. The brains of
homozygous mice contained more soluble as well as insoluble Ab in comparison to hemizygous mice. Data are expressed as means + SEM. Tg,
hemizygous transgenic mice; tg/tg, homozygous transgenic mice. * p,0.05, ** p,0.01, tg versus tg/tg at the respective age (unpaired t-test). C, D,
Correlation of insoluble Ab and plaque load calculated by Acapella
TM software. Insoluble Ab40 (C) and Ab42 (D) were extracted from one brain
hemisphere of hemizygous ARTE10 mice of different age (4 to 15 months old). Plaque load was calculated by Acapella
TM image analysis software
from sections of the corresponding second hemisphere after staining against b-amyloid. A strong correlation between plaque burden and insoluble
Ab was found. C, R
2=0.86; D, R
2=0.69.
doi:10.1371/journal.pone.0007931.g003
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The ARTE10 mouse model exhibits a neuropathological
phenotype that mimics several characteristics of human AD. In
particular, ARTE10 mice develop AD-like cerebral b2amyloid-
osis with respect to the morphology and composition of amyloid
plaques as well as their progressive spatial and temporal pattern of
distribution. Emulating the classical tripartite morphology of senile
plaques in human AD [14], the plaques of ARTE10 mice
invariably consist of the three principal components: (1) a dense
core deposit of congophilic Ab in the centre, surrounded by (2)
numerous ubiquitin-positive dystrophic neurites and by (3) glial
inflammation represented by reactive astrocytes and activated
microglia. Individual plaques sizes and maximum cortical plaque
burden are similar to the respective findings in human AD [6,15].
The absence of full-blown neurofibrillary changes, i.e. argyrophilic
neurites, neurofibrillary tangles or neuropil threads, is in line with
other transgenic mouse models based on the (co-)expression of
APP and presenilin mutants which also lack neurofibrillary
pathology. However, homozygous ARTE10 animals aged 8
months or older show some nascent tau hyperphosphorylation in
few plaque-associated dystrophic neurites. Similar findings have
only been reported in a few other APP-PS1 mouse models [16,17].
The accumulation of ubiquitin is involved in the development of
neurofibrillary changes [18].
We found intracellular Ab in several pyramidal neurons of the
cortex and hippocampus already in young ARTE10 mice that had
not yet developed plaques. The speckled distribution of Ab
immunoreactivity within the neuronal perikarya closely resembles
the intracellular Ab immunoreactive pattern documented for
human AD as well as some other murine AD models, where it is
detectable in vulnerable brain regions preceding plaque deposition
and the development of neurofibrillary changes [19,20]. Interest-
ingly, we could show a similar pattern of intracytoplasmic
immunoreactivity by the anti-oligomer conformation-specific
antibody A11 in some neurons, suggesting that intraneuronal Ab
is at least in part present in an oligomeric state early-on in
ARTE10 mice (Fig. S6).
Plaque deposition starts at 3 and 5 months respectively in
homozygous and hemizygous ARTE10 mice. Plaque burden is
steadily progressive and follows a saturation curve. The spatial and
temporal distribution of plaques primarily and predominantly
involves the hippocampus, the neocortex, and limbic cortical areas
such as the amygdala. Subcortical structures are affected later and
the cerebellum seems to be spared even in aged mice. This pattern
and sequence of brain regions is equivalent to the spatio-temporal
Figure 4. In vivo binding of [
3H]PIB to amyloid plaques. A, Ex vivo digital autoradiography co-registered to its optical scan of a coronal brain
section at about 20.94 Bregma of a 17 months old hemizygous female ARTE10 mouse killed 40 min after intravenous administration of [
3H]PIB. The
dotted pattern demonstrates uptake of tracer in Ab aggregates of cortical and thalamic regions. B, Immunofluorescence stain for Ab40 (green), Ab42
(red) and nuclei (blue) of a close parallel section. Insets: single plaque taken from marked positions. Arrowheads: Tracer binding and Ab staining of
amyloid-b in vessels. Scale bars in overview: 1 mm. Color and scale bars in insets: 100 mm
doi:10.1371/journal.pone.0007931.g004
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the plaque morphology, distribution pattern and sequence of
plaque formation in ARTE10 mice are relatively similar to some
of the other APP and presenilin expressing mouse lines, although
in some cases different promoters and even different APP and/or
presenilin mutants have been used [2,4,25,26]. However, in some
models like APPPS1-21 and Tg2576 mice, amyloid plaques could
also be observed in the cerebellum ([16], unpublished observation),
which is neither the case in ARTE10 mice nor human patients.
Amyloid angiopathy of intracortical, leptomeningeal and choroi-
dal blood vessels is a regular concomitant of human AD [14], and
it is found likewise in ARTE10 animals with advancing
amyloidosis. This is in line with established transgenic mouse
models in which both parenchymal and vascular amyloidosis could
be found [27]. Other models were described that exhibit either
predominantly parenchymal [16] or only vascular amyloid [28].
Ab42 constitutes the predominant insoluble Ab species in
homozygous as well as hemizygous ARTE10 mice, which is in
accordance with other transgenic lines co-expressing APPswe and
mutant PS1 [29,30]. This probably accounts for the early and
robust amyloid deposition in ARTE10 mice. Accordingly, higher
ratios of Ab42 over Ab40 were also observed in human patients
with PS1 mutations [31].
We observed one difference between ARTE10 mice and human
AD: Whereas in human brain diffuse plaques precede mature
amyloid plaques [32], in ARTE10 brain, inversely, diffuse Ab
deposits only became detectable as small ‘‘satellites’’ in proximity
to substantial amounts of mature plaques. Taking advantage of
this, the model is particularly qualified for the purpose of in vivo
validation of substances mainly interacting with mature amyloid
plaques, e.g. radiotracers for in vivo diagnostic imaging and
quantification of amyloid plaques in patients’ brains [12,33]. Here,
we have demonstrated visualization of plaques in ARTE10 brain
ex vivo after intravenous injection of a radiotracer. An in vivo PET
study of Ab in ARTE10 mice using [
11C]-labeled PIB is reported
separately (Manook et al, submitted).
The onset, development and maximal amount of amyloid plaque
deposition vary considerably between established mouse lines (co-)
expressing APP and presenilin mutants [3]. The homozygous
ARTE10 is among those lines displaying a relatively early plaque
onset and a high maximal plaque burden (table 1)[16,26,29,34–37].
However, direct comparisons of published data are very difficult as
quantification methods have not been standardized and studies
comparing different mouse lines are largely missing. 100%
penetrance of the plaque phenotype is rarely reported in the
literature but is an important feature of a model for the use in
amyloid-lowering experiments and likewise a measure of variability.
By 5 months of age, two months after plaque onset, the brains of all
homozygous ARTE10 mice examined exhibited amyloid plaques.
Only for TgCRND8 mice expressing the APP with swedish and
indiana mutations 100% penetrance was reported at an earlier age
[26]. The variability in plaque load between mice of the same age is
relatively low in homozygous ARTE10 mice but comparable to
other models expressing both APP and PS1 at an equivalent age.
For several AD models gender differences have been reported but
were not observed in the hemi-as well as homozygous ARTE10 line
[34,38–41].
ARTE10 mice can be crossed and maintained as double
homozygous line for both APP and PS1 transgenes which has, to
the best of our knowledge, not been described before. Intercrossing
of the line to homozygosity was facilitated by the heredity co-
transmission of the APP and PS1 transgenes. Also, crossing to
gene-targeted mice, for the validation of drug targets directly on an
AD background [42], or to other transgenic lines, e.g. tau
expressing mice, thereby creating a mouse model comprising of
both plaques and tangles, may be simplified. The breeding
performance and viability of ARTE10 mice, backcrossed to
C57BL/6, is undistinguishable from wild type mice, even as
homozygous line. We observed 15% mortality in homozygous
mice at 12 months which is very low in comparison to reports from
other established AD models, as far as data are published.
Figure 5. mRNA expression analysis of synaptic marker proteins
in the brain of ARTE10 mice. A, Synaptophysin (Syp), B, Disk large
homolog 4 (Dlgh4), and C, Drebrin (Dbn1) mRNA expression in
hemizygous and homozygous ART10 mice were analyzed in comparison
to wild type animals. Material from comparable brain regions of mice
ranging from 3 to 13 months of age was used for each of these studies.
mRNA has been extracted from the brain material and expression of
Synaptophysin, Disk large homolog 4, and Drebrin was measured
applying real-time quantitative PCR. For normalization, each ratio of
Synaptophysin, Disk large homolog 4, and Drebrin values with
Cyclophilin B (Ppib) have been calculated and are shown as linear
regression lines. In comparison to wild type mice hemi- as well as
homozygous mice revealed a significant lower mRNA level of Synapto-
physin(p=0.0011;0.0003),Disklargehomolog4(p=0.0003;0.0011),and
Drebrin (p=0.0003; 0.0002) respectively (see also Fig. S9); statistical
analyses were done by Mann-Whitney test. Additionally, in wild type
mice mRNA expression of Dlgh4 and Dbn1 were decreased with aging
(p=0.0013; 0.0253); no such decrease with aging was shown for
Synaptophysin (p=0.5140). Analysis was done by regression diagnostic.
doi:10.1371/journal.pone.0007931.g005
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longitudinal cohort are impaired in spatial learning. Animals were trained to learn the position of a hidden escape platform in the water pool. In the
longitudinal study animals were tested repeatedly every 4 months until they reach 12 months of age. In the cross sectional study design different
testing groups with naı ¨ve animals were used at each time point. Each data point represents the mean of 6 trials per animal. (*) p=0.0407 between
groups over days (repeated measures ANOVA); (#) wt v/s tg/tg, p=0.0154 (unpaired t-test). B, After completion of the water maze training memory
for the platform position in the target zone was assessed during a probe trial in which the platform was removed from the pool. For each group the
percentage time in target zone (filled bar) is shown in comparison to the mean percentage time for the other three zones (open bar). (+) #12.5%, tg,
p=0.052; tg/tg, p=0.052 (one sample t-test). Data are expressed as means + SEM. Dotted lines represent chance levels (12.5%). C, Performance of
mice in the object recognition test. Naı ¨ve homozygous ARTE10 mice display deficits in episodic memory at 12 months of age as demonstrated by
lacking preference for a new over an old object. Preference for the new object (filled bar) is expressed as percentage exploration time in comparison
to exploration of the old object (open bar). Data are expressed as means + SEM. ($)#50%, tg/tg, p=0.293 (one sample t-test); tg, hemizygous
transgenic mice; tg/tg, homozygous transgenic mice; Wt, wild type litter mates.
doi:10.1371/journal.pone.0007931.g006
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used Tg2576 and TgCRND8 mice on C57Bl/6 background at 12
and 9 months respectively [26,43]. Others describe mortality
between 21–70% dependent on expression levels in different
APPswe lines at 12 months of age [44].
We have developed and used a novel image analysis algorithm
for the quantitative assessment of the plaque load, number per
area and size distribution of amyloid plaques in defined regions of
the mouse brain. These morphological parameters can be of
importance in amyloid-lowering therapies, e.g. in which the
plaque number appears to be more sensitive than total amyloid
burden [45]. Different attempts have been made to implement
computer-assisted analysis for quantification of amyloid plaques on
human and mouse brain sections [25,46]. A frequent difficulty of
image analysis is identification of false positive structures arising
from background staining and tissue artefacts, thereby lowering
the specificity and reliability of object recognition. The here
described algorithm based on the Acapella
TM image analysis
software implements multi-channel segmentation and dynamic
thresholding for elimination of tissue background and artefacts
thus outperforming the common global threshold based methods
[25]. In order to test the validity and reliability of our novel
Acapella procedure, morphological and biochemical analyses were
conducted in parallel on ARTE10 mice at different ages. Plaque
loads were determined by Acapella in one brain hemisphere, and
levels of insoluble Ab extracted with formic acid from the
contralateral brain hemisphere of the same animal were measured
by ELISA. The quantitative results of the two different approaches
strongly correlated with each other. Thus, the validity and
reliability of our novel morphological procedure have been
confirmed successfully by the use of an independent, conventional
ELISA method.
Synaptic loss and dysfunction already occur at very early stages
of AD [47,48] mirrored by a decrease of pre- and post-synaptic
marker proteins synaptophysin [49–51], Disk large homolog 4
(DLGH4 [52]) and Drebrin (DBN1 [53–55]). Whereas a direct
spatial relationship of amyloid plaque deposition to synaptic loss
was shown in AD mouse models [56–58], synaptic deficits have
been shown to also occur prior to plaque deposition [59,60].
Analyses of ARTE10 mouse brains at different points of age
revealed decreased mRNA levels of all three synaptic marker
proteins already at 3–4 months of age. Such decreased mRNA
levels are of the same magnitude in both hemi- and homozygous
ARTE10 mice in contrast to the respective gene dose-dependent
differences in the amount and onset of plaque deposition. This
observation is in accordance with early-onset synaptic defects as
described in other AD mice [59,60].
By the age of 12 months, ARTE10 mice developed cognitive
deficits mainly in episodic memory, which is in accordance with
observations made in other mouse models [61]. A subtle spatial
learning deficit was only observed in mice of the longitudinal
group that were tested repeatedly and can be explained by an
impaired flexibility of transgenic mice as has been found in other
transgenic APP-PS1 mice [16] and human AD patients [62]. At
the age when cognitive deficits occur, the plaque load has already
reached an advanced stage implying a direct link between plaque
deposition and cognitive impairment as suggested in previous
studies [63]. Other studies showed a correlation between
cognitive deficits and soluble, oligomeric forms of Ab as
explanation for cognitive deficits before the appearance of first
plaques [64]. However, analyses with human AD patients are
largely missing and needed to clarify the role of Ab in this
process.
Finally, levels of soluble Ab in the brain could be reduced by
acute treatment of ARTE10 mice with a c-secretase inhibitor. In
accordance with the literature we could find a dosage-dependent
inhibition of Ab40 secretion by maximal 75% [11]. Ab42 levels
were reduced by 25% which has not been reported before for this
c-secretase inhibitor. In summary, these results demonstrate the
suitability of the transgenic model in the development and
exploration of amyloid-lowering therapies.
In conclusion, the double-transgenic APP-PS1 mouse line
ARTE10 unifies several features for a meaningful and easy to
use model for AD-like cerebral b-amyloidosis i) an early-onset and
rapid progression of plaque load, ii) plaques showing similar
morphology to those in human AD, iii) low inter-animal variability
and no gender effects, iv) the co-inherited transgenes and a
C57BL/6 background facilitate breeding to other transgenic or
gene-targeted mice, v) good breeding capabilities of the homozy-
gous line and a low rate of premature death, vi) early loss of
synaptic markers and age-related cognitive deficits. Together with
the described plaque load analysis and as demonstrated by using a
c-secretase inhibitor, ARTE10 is well suited for testing of Ab-
modulating treatment protocols and may also be of use in target
validation approaches.
Figure 7. Effect of a c-secretase inhibitor on soluble brain Ab40
and Ab42. MRK-560/compound 32 was applied p.o. to hemizygous
transgenic mice and brain Ab levels were analysed 4 h post-dosing.
Soluble Ab40 (A) and Ab42 (B) were significantly reduced after
treatment with the c-secretase inhibitor. Data are expressed as means
+ SEM. (*) p=0.0176, (**) p,0.005, (***) p,0.0001 versus vehicle.
doi:10.1371/journal.pone.0007931.g007
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Supporting File S1 Supplemental results and methods.
Found at: doi:10.1371/journal.pone.0007931.s001 (0.02 MB
PDF)
Figure S1 Specific immunofluorescent detection of the transgenic
human, but not endogenous murine, APP protein in ARTE10
mouse brains with the human-specific anti-APP N-terminal mouse
monoclonal antibody LN27. The transgenic human protein is
clearly detected in a neuronal pattern on brain sections from an 8
months old homozygous female (A–C), a 4 months old hemizygous
female (G–K), and a 4 months old hemizygous male (L–N) mouse.
Endogenous mouse APP is not labelled on brain sections from an 8
months old female wild type littermate (D–F). (A, D, G, L) frontal
neocortex. (B, E, H, M) posterior neocortex, parts of the subiculum
and the CA1region of the hippocampus. (C, F, K, N) hippocampus.
All micrographs were taken and are shown at the same
magnification. Scale bar in (A), 200 mm.
Found at: doi:10.1371/journal.pone.0007931.s002 (4.99 MB TIF)
Figure S2 Plaque detection with Acapella
TM. (A) Digital
micrograph of a mouse brain section stained against amyloid b.
Regions of interest (neocortex and hippocampus) are marked
manually. (B) Original image reduced to neocortex and hippo-
campus. (C) Image is split into hue, saturation, and value (HSV)
channels. (D) The image analysis algorithm detects stained
structures by individually segmenting the HSV channels. Channel
results are connected in order to retrieve plaque load, size, and
number. (E) Outcome of plaque detection visualized with green
labels. For details please refer to the Methods section.
Found at: doi:10.1371/journal.pone.0007931.s003 (5.13 MB TIF)
Figure S3 Double-immunofluorescent detection of Ab40 (green)
and Ab42 (red) in the cortex of a 10 months-old homozygous
ARTE10mouse(blue,nuclei/DAPI).Most plaques aredense-cored
and contain both Ab40 and Ab42 species, resulting in merged
yellow color. The arrows point to some diffuse deposits consisting of
Ab42 (for details, see text). Scale bars: A, 200 mm; B, 50 mm.
Found at: doi:10.1371/journal.pone.0007931.s004 (8.70 MB TIF)
Figure S4 Left column: Thioflavin-S positive plaque cores
(green), each encircled by a sphere (corona) of dilated, strongly
ubiquitin-positive dystrophic neurites (red) in the cortex of four
homozygous ARTE10 mice between 5 and 13 months of age.
Right column: Triple-immunofluorescent demonstration of
plaque-associated mixed glial inflammation: Activated microglia
(green, AIF1/Iba1) and reactive astroglia (magenta, GFAP)
colonizing the periphery of amyloid cores (red: Ab/6E10) in the
cortex of four homozygous ARTE10 mice between 5 and 13
months of age (blue: nuclei/DAPI). Scale bars, 50 mm each.
Found at: doi:10.1371/journal.pone.0007931.s005 (9.86 MB TIF)
Figure S5 Triple-immunofluorescent detection of the pre-
synaptic marker protein synaptophysin (green) accumulating in
plaque-associated swollen dystrophic neurites of the plaque
corona, apart from its physiological localization in the neuropil.
Co-staining with the somato-dendritic marker MAP2 (magenta),
with human APP (red) and nuclear staining with DAPI (blue). A,
Subiculum of a 9 months-old hemizygous ARTE10 mouse. B,
Dentate gyrus of a 7 months-old homozygous ARTE10 mouse. C,
frontal cortex of an 8 months-old homozygous ARTE10 mouse.
Scale bar for all three images, 50 mm.
Found at: doi:10.1371/journal.pone.0007931.s006 (10.00 MB
TIF)
Figure S6 Immunofluorescent detection of intracellular Ab
(green) by 4G8 (A, B) or AB1 (C) in cortical neurons, shown here
in two young ARTE10 animals (1 and 3 months). APP is co-
stained in red in the left two images. The speckled intracytoplas-
mic Ab immunostaining is paralleled by virtually the same pattern
detected by the anti-oligomer conformation-specific antibody A11
(green, D) within the perikarya. This pattern closely resembles the
intracellular Ab immunoreactivity of affected neurons in human
AD as well as in other murine AD models and suggests that
intraneuronal Ab is at least in part present in an oligomeric state
early-on in ARTE10 mice. Scale bar in (A), 10 mm.
Found at: doi:10.1371/journal.pone.0007931.s007 (4.51 MB TIF)
Figure S7 Thioflavin-S staining (green, FITC channel) for
fluorescent detection of amyloid plaques in parasagittal brain
Table 1. Comparison of amyloid burden in transgenic mouse models of AD.
Mouse model Transgenes
a Plaque onset 100% penetrance Plaque load in aged mice
b, c Ref.
Tg2576 PrP-APPswe ,9 m (6–11 m) 11–13 m 6.077+/2 0.99 (24 m) [2,35,65]
APP23 thy1-APPswe 6–9 m 18 m 24.1+/2 0.9% (15.9–28%, 27 m) [27,66,67]
TgCRND8 PrP-APPswe,ind 2–3 m 3 m ,4% (9–11 m) [26,63]
Tg2576 x PrP-APPswe x 3 m n.r. Cx: 52% (28–64%, 15 m) [68,69]
PS1 5.1 PDGF-PS1M146L Hx: 25% (10–42%, 15 m)
APPPS1-21 thy1-APPswe + Cx: 1.5 m n.r. Cx: 20.9+/2 0.8% (19 m) [16]
thy1-PS1L166P
d Hx: 2–3 m Hx: 9.6+/2 0.4% (19 m)
PS2APP thy1-APPswe x PrP-PS2N141I 5 m n.r. 5.5+/2 1.5% (17–18 m) [4]
ARTE10 thy1-APPswe + 5 m 10 m 10.5+/2 2.2% This
(tg) thy1-PS1M146V
d (0.2–35.6%, 19–20 m) paper
ARTE10 thy1-APPswe + 3m 5m 3 5 . 2 +/2 2.8% This
(tg/tg) thy1-PS1M146V
d (26.4–53.2%, 19–20 m) paper
cx, cortex; hx, hippocampus; m, months; n.r., not reported; PrP, prion protein; tg, hemizygous; tg/tg, homozygous.
apromoter-cDNA.
b+/2 SEM, range and age in brackets.
cin cortex and hippocampus.
dco-injected.
doi:10.1371/journal.pone.0007931.t001
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ARTE10 mice at different ages (3, 8, 12, and 20 months),
illustrating the effects of age and gene dose on the plaque load.
Tissue autofluorescence recorded in the red/Cy3 channel (in the
absence of fluorophore) is utilized for the morphological
visualization of gross anatomical structures. The sections are
always oriented with the cortex at the top, the anterior part at the
left, the posterior part at the right. Fluorescent micrographs were
recorded separately for each channel by means of a Olympus
BX51 microscope using the appropriate dichroic mirrors and
filters, a 2x objective, a 0.5x TV adapter, and a ColorView-II
CCD camera. The channels were merged using the Olympus
analySIS ‘‘FIVE’’ imaging software. Parallel sections from the
same animals as in Figure S8 are shown.
Found at: doi:10.1371/journal.pone.0007931.s008 (9.56 MB TIF)
Figure S8 Immunohistochemical detection of Ab (6E10, green)
in parasagittal brain sections of representative hemi- (tg) and
homozygous (tg/tg) ARTE10 mice at different ages (3, 8, 12, and
20 months), illustrating the effects of age and gene dose on the
plaque load.
Found at: doi:10.1371/journal.pone.0007931.s009 (10.17 MB
TIF)
Figure S9 Statistical analysis of synaptic marker mRNA
expression analysis. A, Synaptophysin (Syp), B, Disk large
homolog 4 (Dlgh4), and C, Drebrin (Dbn1) mRNA expression
in hemizygous and homozygous ART10 mice were analyzed in
comparison to wild type animals. Material from comparable brain
regions of mice ranging from 3 to 13 months of age was used for
each of these studies. mRNA has been extracted from the brain
material and expression of Synaptophysin, Disk large homolog 4,
and Drebrin was measured applying real-time quantitative PCR.
For normalization, each ratio of Synaptophysin, Disk large
homolog 4, and Drebrin values with Cyclophilin B (Ppib) have
been calculated. In comparison to wild type mice hemi- as well as
homozygous mice revealed a significantly lower mRNA level of
Synaptophysin (p=0.0011; 0.0003), Disk large homolog 4
(p=0.0003; 0.0011), and Drebrin (p=0.0003; 0.0002), respec-
tively; statistical analyses were done by Mann-Whitney U-test.
Found at: doi:10.1371/journal.pone.0007931.s010 (0.10 MB TIF)
Table S1 Results of tests examining body weight, body
temperature and motor-sensory abilities of hemizygous and
homozygous transgenic mice in comparison to wild type
littermates. Data are expressed as means +/2 SEM; * p,0.05
versus wild type littermates (Wt); Tg hemizygous transgenic mice;
Tg/tg homozygous transgenic mice.
Found at: doi:10.1371/journal.pone.0007931.s011 (0.01 MB
PDF)
Table S2 Results of behavioural tests examining locomotor and
exploratory activity, anxiety and spontaneous alternation of
heterozygous and homozygous transgenic mice in comparison to
wild type littermates. Data are expressed as means +/2 SEM;
*p ,0.05 versus wild type littermates (Wt); # p,0.05 versus
hemizygous littermates (Tg); Tg/tg homozygous transgenic mice.
Found at: doi:10.1371/journal.pone.0007931.s012 (0.01 MB
PDF)
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